GURUFOCUS.COM » STOCK LIST » Latin America » Mexico » MEX » Biogen Inc (MEX:BIIB) » Definitions » Net Current Asset Value
Switch to:

Biogen (MEX:BIIB) Net Current Asset Value

: MXN-129.37 (As of Mar. 2023)
View and export this data going back to 2013. Start your Free Trial

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Biogen's net current asset value per share for the quarter that ended in Mar. 2023 was MXN-129.37.

The historical rank and industry rank for Biogen's Net Current Asset Value or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Biogen was 727.40. The lowest was 0.26. And the median was 13.31.

MEX:BIIB's Price-to-Net-Current-Asset-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.22
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Biogen Net Current Asset Value Historical Data

The historical data trend for Biogen's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Current Asset Value
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -458.85 -596.47 -917.79 -715.14 -184.81

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Net Current Asset Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -601.54 -480.50 -323.08 -184.81 -129.37

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Net Current Asset Value, along with its competitors' market caps and Net Current Asset Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen Net Current Asset Value Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Net Current Asset Value distribution charts can be found below:

* The bar in red indicates where Biogen's Net Current Asset Value falls in comparison to its industry or sector. The grey bar indicates the Net Current Asset Value's extreme value range as defined by GuruFocus.



Biogen Net Current Asset Value Calculation

Biogen's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2022 is calculated as

Net Current Asset Value Per Share(A: Dec. 2022 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(190889.235-217686.487--185.212-0)/144
=-184.81

Biogen's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2023 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(175969.062-194875.485--173.04-0)/144.8
=-129.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen  (MEX:BIIB) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Biogen Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Biogen's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (MEX:BIIB) Headlines

From GuruFocus

Other Sources

Is Biogen Stock a Buy Now?

By Yahoo Finance 2023-01-26